Background
==========

Asthma is a common respiratory disease that is characterized by bronchial hyperresponsiveness and airway obstruction due to chronic airway inflammation \[[@B1]\]. These processes are attributed to the increased expression of genes for several inflammatory and immune mediators, including cytokines, chemokines, adhesion molecules, enzymes, and chemical mediators \[[@B2]\]. The complex traits that result from interactions between multiple disease susceptibility factors and the surrounding environment have major influences on the onset and severity of asthma \[[@B3]\].

Atopic asthma is a typical IgE-mediated disease in which the enhanced production of IgE is driven by the activation of Th2 cells, which release a distinct pattern of cytokines, including interleukin 4 (IL4) and IL3, in response to specific antigen presentation \[[@B4],[@B5]\]. Atopy, which is characterized by the presence of IgE specific for inhalant allergens or by high-level production of IgE, is closely associated with asthma development \[[@B6]\]. The prevalence of asthma has increased throughout the world over the past three decades \[[@B7]\]. However, wide variations have been noted among populations of the same races, indicating different exposures to environmental factors \[[@B8]\]. Environmental factors during the pre- and post-natal periods, including the extent of allergens such as obesity, and exposure to smoking and air pollutants are risk factors for asthma. Furthermore, asthma is triggered and exacerbated by outdoor allergens and air pollutants, including pollens, and microbial and viral pathogens \[[@B9]-[@B11]\]. It is noteworthy that many of these indoor and outdoor inducers/triggers of asthma program the immature airway during early life, without any effect on the host DNA, leading to altered asthma risk in later life \[[@B12]\]. Epigenetics consists of changes in gene expression due to mechanisms other than changes to the underlying DNA sequence \[[@B13],[@B14]\]. These changes may induce phenotypic change and persist through cell divisions for the remainder of the cell\'s life, possibly lasting for multiple generations without any change in the intrinsic DNA sequence of the organism. Epigenetic changes include histone deacetylation, DNA methylation and non-coding RNAs. The DNA methylation is the covalent addition of a methyl group to a cytosine residue in a CpG dinucleotide \[[@B15]\]. Regions of methylated DNA have been correlated with the tissue-specific expression of several genes and with active coding regions across the genome \[[@B16]\]. Recently, transitory methylation has been demonstrated for specific gene regulatory regions \[[@B17]\]. DNA methylation analysis can be grouped into the mutually exclusive categories of annotated promoters (15%), untranslated regions (UTRs; 7%), exons (13%), introns (31%), and intergenic segments (34%) according to each regions \[[@B18]\]. However, the global distribution of DNA methylation in human bronchial mucosa tissue is unknown, and its role in the development of asthma has not been reported to date.

The airway inflammation and remodeling that occur in asthma are characterized by the infiltration of lymphocytes and eosinophils into the bronchial mucosa, accompanied by structural changes, which include epithelial desquamation, subepithelial fibrosis, mucus gland hyperplasia, modification of the extracellular matrix, and hypertrophy/hyperplasia of smooth muscle cells \[[@B19],[@B20]\]. Thus, bronchial mucosa tissues are suitable for studying the role of epigenetics in airway responses to environmental factors, such as indoor allergens. In the present study, using microarray analyses, we analyzed the genome-wide DNA methylation profiles of bronchial mucosa tissues from two groups of asthmatics who lacked or carried specific IgE to the dust mites *Dermatophagoides farina* (*Df*) and *Dermatophagoides pteronyssinus* (*Dp*), and from normal controls, to reveal the epigenetic differences between house dust mite-sensitized subjects and naïve subjects.

Methods
=======

Subjects
--------

All samples were obtained after an informed, written consent was obtained from each patient and the protocol was approved by the local ethic committee (The ethics committee\'s approval number: SCHBC-IRB-2005-02). The bronchial mucosa tissues from atopic asthmatics for *Df* and *Dp* (N = 10), non-atopic asthmatics (N = 7), and normal controls (N = 7) were obtained from the Biobank after the experimental protocol was approved by the Ethics Committee in the biobank of Soonchunhyang University Hospital (Schbc-biobank-2011-004). All patients were diagnosed by physicians and met the definition of asthma provided in the Global Initiative for Asthma (GINA) guidelines \[[@B1]\]. All patients had a history of dyspnea and wheezing during the previous 12 months, plus one of the following: 1) \>15% increase in forced expiratory volume in 1 second (FEV~1~) or \>12% increase plus 200 mL following inhalation of a short-acting bronchodilator; 2) \<10 mg/mL PC20 methacholine; or 3) \>20% increase in FEV~1~ following 2 weeks of treatment with inhaled or systemic corticosteroids. The normal subjects, who were recruited from the spouses of the patients and from the general population, answered negatively to a screening questionnaire for respiratory symptoms \[[@B21]\] and had an FEV1 *\>*75% of the predicted value, PC20 methacholine *\>*10 mg/ml, and normal findings on a plain chest X-ray.

Allergy skin prick tests and specific IgE measurements
------------------------------------------------------

Allergy skin prick tests were performed using 24 commercial inhalant allergens, which included dust mites (*Df* and *Dp*), fungi, cat fur, dog fur, cockroaches, and grass, tree, and weed pollens (Bencard Co. Ltd., Brentford, UK). All of the tests included positive (1 mg/mL histamine) and negative (diluent) controls. Atopy was defined as having a wheal reaction equal to or greater than 3 mm in diameter or equal to or greater than that induced by histamine. IgE specific for *Df* and *Dp* was measured using the CAP system (Pharmacia Diagnostics, Uppsala, Sweden). The concentrations were measured in kU/l and expressed semi-quantitatively as classes 0--6. Sensitization to house dust mites was confirmed by a positive skin prick test to house dust mites and elevated allergen-specific IgE level (greater than score 2). Non-atopy was defined as a negative skin prick test to all allergens tested and a negative result for specific IgE (score 0) raised in response to *Df* and *Dp*.

Genomic DNA isolation
---------------------

All the mucosal biopsies had been taken from the segmental carinae of the right lower lobe, fixed in 4% buffered formaldehyde solution, and embedded in paraffin blocks. DNA was purified from the tissues using the QIAamp DNA Blood Mini Kit (Qiagen, Crawley, UK).

Bisulfite conversion
--------------------

Bisulphite conversion of genomic DNA was done with the EZ DNA methylation Kit (Zymo Research, Irvine, CA, USA) by following the manufacturer\'s protocol with modifications for the Illumina Infinium Methylation Assay. Briefly, one microgram of genomic DNA was first mixed with 5 μl of M-Dilution Buffer and incubated at 37°C for 15 minutes and then mixed with 100 μl of CT Conversion Reagent prepared as instructed in the protocol. Mixtures were incubated in a thermocycler for 16 cycles at 95°C for 30 seconds and 50°C for 60 minutes. Bisulphite-converted DNA samples were loaded onto 96-column plates provided in the kit for desulphonation and purification as instructed in the protocol.

DNA methylation assay and differential DNA methylation analysis
---------------------------------------------------------------

Bisulphite-converted genomic DNA was analyzed using Human Methylation27 Beadchip (Illumina, San Diego, CA, USA). The beadchip contains 27,578 CpG loci covering more than 14,000 human RefSeq genes at single-nucleotide resolution. Chip process and data analysis were performed by using reagents provided in the kit and by following the manufacturer\'s manual. Briefly, 4 μl of bisulphite-converted genomic DNA was denatured in 0.014 N sodium hydroxide, neutralized and amplified with kit-provided reagents and buffer for 20--24 hours at 37°C. Samples were fragmented. 12 μl of each sample was loaded onto a 12-sample chip and the chips were assembled into a hybridization chamber as instructed in the manual. After incubation at 48°C for 16--20 hours, chips were washed with wash buffers provided in the kit and assembled and placed into a fluid flow-through station for primer-extension reaction and staining with reagents and buffers provided in the kit. Polymer-coated chips were image-processed in Illumina\'s iScan scanner. Data were extracted using GenomeStudio software. Methylation values for each CpG locus are expressed as a beta (β)-value, representing a continuous measurement from 0 (completely unmethylated) to 1 (completely methylated). This value is based on following definition and calculation: β-value = (signal intensity of methylation-detection probe)/(signal intensity of methylation- detection probe + signal intensity of non-methylation-detection probe). The intensity data were normalized using the background function.

Statistics analysis
-------------------

To identify differentially methylated CpG sites between the groups, the difference in mean methylation levels between the two groups was analyzed using a two-sided *t*-test. Assuming a normal distribution of β-value, DeltaBeta (\|Δβ\|) was calculated as β for the bronchial asthma (BA) group minus that for the normal control (NC) group or atopic asthmatics minus that for the non-atopic ones. Selection of the differentially methylated CpG loci between groups was based on (1) a β-value difference of \>0.10 and (2) a P-value of \<0.01. Heatmap of the differentially methylated CpG sites was done and viewed by GenomeStudio software. Gene ontology enrichment of DNA methylation profile was performed using GOTM (<http://bioinfo.vanderbilt.edu/gotm/>), which is based on hypergeometric test to show the overrepresented gene ontology categories (p-value \< 0.01) \[[@B22]\]. The p-value was also calculated according to BINOMDIST function on the basis of the overrepresentation of gene ontology categories in hypermethylated and hypomethylated genes when comparing to all genes on the chip, as a confirmation of the significance of results.

Statistical analyses were performed with SPSS 10.0. The Mann--Whitney test (two-sample rank-sum test) was used to analyze differences between two groups. All data are expressed as median values and interquartile ranges; significance was defined as *P* \<0.05.

Results
=======

Clinical characteristics of the study subjects
----------------------------------------------

The 17 patients with asthma were classified into two groups (atopic and non-atopic to *Df* or *Dp*) based on the results of the skin tests and assays for specific IgE to *Df* and *Dp*. The characteristics of the asthmatics and normal controls are summarized in Table [1](#T1){ref-type="table"}. There were no significant differences in terms of age, sex, smoking ratio, and FEV1 between the atopic and non-atopic patients. The total IgE concentration and the level of specific IgE to *Df* and *Dp* were significantly higher in the atopic group than in the non-atopic group (*P* \< 0.03, and *P* \< 0.001, respectively).

###### 

Clinical characteristics of patients with bronchial mucosa tissues for DNA Methylation chip

       **Clinical profile**            **NC**       **Atopic asthmatics**   **Non atopic asthmatics**   **P-value**  
  ------------------------------- ---------------- ----------------------- --------------------------- ------------- -------------
              Number                     7                   10                         7                                   
        Age, years (range)          50 (22--71)          35 (21--60)               47 (28--78)             0.288         0.133
          Sex, male, n(%)             1 (14.3)             4 (40)                   1 (14.3)               0.629         0.338
      exsmoker/nonsmoker (%)           0 / 7                2 / 8                     1 / 6                0.299         0.677
   Positive skin test rate (%)\*         ND                 100\*                       0                  **-**      **0.00005**
         FVC (% predicted)         89.20 ± 10.18        79.50 ± 16.89             90.80 ± 22.26            0.349         0.371
       FEV~1~ (% predicted)        102.00 ± 16.84       78.50 ± 22.54             90.60 ± 20.77            0.119         0.44
     FEV~1~/FVC (% predicted)       85.80 ± 6.18        77.00 ± 15.12             76.20 ± 6.10             0.168         0.513
      Body mass index (kg/m2)       23.37 ± 4.08        25.31 ± 1.66              25.92 ± 3.20             0.497         0.37
         Total IgE (IU/M)               37.2           663.95 ± 784.99           111.28 ± 99.90            0.267       **0.036**
    *Dp.* specific IgE (score)           ND               4 (2--6)                      0                   \-        **0.0005**
    *Df.* specific IgE (score)           ND               4 (2--6)                      0                   \-        **0.0005**

Data are presented as mean ± standard deviation or as median (range).

\*Positive skin prick test to house dust mites(*D. pteronyssinus, or D. farina*)*.*

BA:Bronchial asthma; NC:Normal control.

Distribution of DNA methylation levels among the three groups
-------------------------------------------------------------

DNA methylation levels were measured with Illumina's genome-wide methylation assay chip of 27 K CpG sites. Methylation of the X-chromosome was not considered in this analysis. Of the 27578 CpG sites, 14363 were located within promoter regions, while 13215 loci were in the gene body. As shown in Figure [1](#F1){ref-type="fig"}, the methylation levels in the three groups showed a similar unimodel distribution, with the highest peak on the *x*-axis (average β, 0.1--0.2) and the lowest peak at the right end (average β, 0.9--1.0). Approximately 50% of the loci had an average β value \<0.2, whereas 0.3% of the loci had an average β value of 0.9--1.0.

![**Distribution of the DNA methylation levels of BA-atopy, non atopy and NC in bronchial mucosa.** Average beta: DNA methylation level (0--1).](1471-2350-14-39-1){#F1}

Comparison of DNA methylation patterns of the BA and NC groups
--------------------------------------------------------------

The methylation levels were similar between the mucosa of the asthmatics and the normal controls (Figure [2](#F2){ref-type="fig"}A). The \|Δβ\| values for the methylation levels were calculated as the average β value for the NC group minus that for the BA group. A volcano plot of the \|Δβ\| values for each locus in the bronchial mucosa tissues is shown in Figure [2](#F2){ref-type="fig"}A-2. The values ranged from −0.2 to 0.2. Although the DNA methylation levels were not remarkably different between the two groups (Figure [2](#F2){ref-type="fig"}A-1), one methylation site in a CpG motif in the promoter of *LCN6* showed a significant difference (*P* \< 0.01) in \|Δβ\| value (0.11) between the two groups (Table [2](#T2){ref-type="table"}).

![**Summary of DNA methylation data.** (**A-1**) Scatter plot of similar methylation levels between BA and NC. (**A-2**) Volcano plot of the \|Db\| values between BA and NC. (**B-1**) Scatter plot of similar methylation levels between BA-atopy and non atopy. DeltaBeta: difference of DNA methylation levels. (**B-2**) Volcano plot of the \|Db\| values between BA-atopy and non atopy. log(P): log-transformed t-test P-values. (**C**) Heat map of 53 methylated CpGs on whole chromosome between the three groups (BA-atopy, BA-non atopy, NC). The DNA methylation profiles were similar between the three groups.](1471-2350-14-39-2){#F2}

###### 

DNA methylation level of CpGs in genes between BA and NC

                                                              **BA vs NC**                                
  --- ------------ ------ --- ----------- ---------- ------- -------------- ------------- ------ -------- -------
   1   cg14611112   LCN6   9   138762801   Promoter   FALSE   0.46 ± 0.07    0.56 ± 0.04   0.11   0.0008   0.005

Comparison of DNA methylation patterns between asthmatics atopic or non-atopic for *Df* and *Dp*
------------------------------------------------------------------------------------------------

The DNA methylation profiles were similar for the two groups, with a narrow range of \|Δβ\| values from −0.2 to 0.2. A volcano plot of the \|Δβ\| values for each locus in the bronchial mucosa tissues is shown in Figure [2](#F2){ref-type="fig"}B-2. To identify the loci that showed atopy-specific changes in methylation, we applied the following criteria: *P* ≤ 0.01 and \|Δβ\| ≥ 0.10. Six loci in six genes in the bronchial mucosa samples showed significant increases in methylation among the atopic patients, as compared to the non-atopic patients, whereas 47 loci in 46 genes showed significant decreases in methylation in these samples (Table [3](#T3){ref-type="table"}). Heat mapping of the β values for the 53 loci revealed distinct DNA methylation profiles for the bronchial mucosa tissues of the atopic and non-atopic groups (Figure [2](#F2){ref-type="fig"}C). Among these loci (n = 53), 24 were located within CpG islands, while 29 were outside CpG islands. In all, 31 loci were identified within promoter regions (2 kb from the transcriptional start site), while 22 loci were in the gene body (Table [3](#T3){ref-type="table"}).

###### 

DNA methylation level of CpGs in genes between BA-atopy and non atopy

                                                                      **BA atopy vs BA non atopy**                                 
  ---- ------------ ----------- ---- ----------- ----------- ------- ------------------------------ ------------- ------- -------- -------
   1    cg15804973    MAP3K5     6    137155349   Promoter    TRUE            0.37 ± 0.06            0.26 ± 0.04   0.11    0.0005    \-
   2    cg18201077     RSAD2     2     6935359    Promoter    FALSE           0.29 ± 0.06            0.19 ± 0.03   0.11    0.001    0.005
   3    cg24262469    TIPARP     3    157875073   Promoter    TRUE            0.42 ± 0.08            0.31 ± 0.03   0.11    0.004     \-
   4    cg23123362     ICF45     5    157091024   Promoter    FALSE           0.39 ± 0.07            0.29 ± 0.03    0.1    0.004    0.007
   5    cg06987504    EIF3S6     8    109330128   Promoter    TRUE            0.33 ± 0.08            0.22 ± 0.04    0.1    0.007     \-
   6    cg27398499    TACSTD2    1    58816033    Promoter    FALSE           0.41 ± 0.08            0.31 ± 0.05    0.1    0.009    0.009
   7    cg23989635     CDH1      16   67328696    Gene body   TRUE            0.16 ± 0.03            0.29 ± 0.07   −0.14   0.0001    \-
   8    cg25368651   C11orf47    11    6475107    Promoter    TRUE            0.64 ± 0.06            0.76 ± 0.02   −0.12   0.0002    \-
   9    cg25427580    B3GALT1    2    168383428   Gene body   TRUE            0.63 ± 0.06            0.74 ± 0.03   −0.11   0.0003    \-
   10   cg18885346     PKHD1     6    52060382    Promoter    FALSE           0.57 ± 0.06            0.68 ± 0.04   −0.11   0.0004   0.013
   11   cg15309006   LOC63928    16   23673449    Gene body   TRUE            0.16 ± 0.05            0.27 ± 0.05   −0.11   0.0005    \-
   12   cg09272256    AKR1C4     10    5228798    Gene body   FALSE           0.56 ± 0.07            0.68 ± 0.03   −0.12   0.0006   0.010
   13   cg11532513     LRTM1     3    54937112    Promoter    FALSE           0.60 ± 0.05            0.71 ± 0.05   −0.11   0.0007   0.007
   14   cg16242770   KRTAP17-1   17   36725473    Gene body   FALSE           0.71 ± 0.06            0.82 ± 0.02   −0.1    0.0007   0.006
   15   cg00051623     CASP1     11   104411067   Promoter    FALSE           0.65 ± 0.07            0.76 ± 0.03   −0.12   0.0008   0.004
   16   cg20587168   MGC33407    19    8670172    Gene body   TRUE            0.33 ± 0.06            0.46 ± 0.07   −0.13   0.0009    \-
   17   cg03355526    ZNF454     5    178300830   Gene body   TRUE            0.28 ± 0.06            0.39 ± 0.05   −0.11   0.001     \-
   18   cg24648061     GPR22     7    106901742   Gene body   FALSE           0.50 ± 0.07            0.62 ± 0.04   −0.12   0.002    0.007
   19   cg11237738    C4orf6     4     5577784    Gene body   FALSE           0.54 ± 0.07            0.64 ± 0.02   −0.1    0.002    0.006
   20   cg03734874   FLJ42486    14   104142142   Promoter    TRUE            0.23 ± 0.06            0.34 ± 0.05   −0.11   0.002     \-
   21   cg20937139     PDGFC     4    158111996   Promoter    TRUE            0.17 ± 0.06            0.28 ± 0.06   −0.11   0.002     \-
   22   cg26657648     IL1R1     2    102136834   Promoter    FALSE           0.64 ± 0.07            0.75 ± 0.03   −0.11   0.002    0.006
   23   cg23111544     REG1A     2    79201092    Promoter    FALSE           0.57 ± 0.07            0.67 ± 0.03   −0.1    0.002    0.005
   24   cg07823755    UGT1A1     2    234333658   Promoter    FALSE           0.71 ± 0.07            0.81 ± 0.03   −0.1    0.002    0.005
   25   cg13112511     PDE4D     5    58918032    Promoter    FALSE           0.59 ± 0.09            0.71 ± 0.03   −0.12   0.002    0.005
   26   cg21717724     PSMD5     9    122645027   Gene body   TRUE            0.47 ± 0.07            0.59 ± 0.06   −0.12   0.002     \-
   27   cg08509737     ATG7      3    11315160    Gene body   FALSE           0.68 ± 0.07            0.78 ± 0.02   −0.1    0.002    0.004
   28   cg05333568    C1orf65    1    221633391   Gene body   TRUE            0.29 ± 0.08            0.43 ± 0.08   −0.14   0.003     \-
   29   cg16398289     WDR49     3    168853983   Promoter    FALSE           0.56 ± 0.08            0.66 ± 0.03   −0.11   0.003    0.006
   30   cg04527918      UCN      2    27384634    Promoter    TRUE            0.42 ± 0.06            0.54 ± 0.08   −0.12   0.003     \-
   31   cg20088913   FLJ46363    12    9997203    Promoter    FALSE           0.57 ± 0.07            0.67 ± 0.03   −0.1    0.003    0.005
   32   cg10430690     KALRN     3    125296275   Gene body   TRUE            0.65 ± 0.09            0.77 ± 0.02   −0.11   0.004     \-
   33   cg15381313     NR1H4     12   99391810    Promoter    FALSE           0.50 ± 0.06            0.60 ± 0.07   −0.1    0.004    0.006
   34   cg17778867   KRTAP10-8   21   44856424    Gene body   FALSE           0.60 ± 0.09            0.71 ± 0.02   −0.12   0.004    0.006
   35   cg01216369    SPATA16    3    174341695   Promoter    TRUE            0.64 ± 0.08            0.74 ± 0.02   −0.1    0.005     \-
   36   cg01507173     IL1F5     2    113532686   Gene body   FALSE           0.59 ± 0.08            0.69 ± 0.02   −0.1    0.005    0.007
   37   cg22152192     CRYM      16   21221918    Promoter    FALSE           0.52 ± 0.08            0.63 ± 0.04   −0.1    0.005    0.007
   38   cg21053323     SUMO3     21   45062472    Gene body   TRUE            0.20 ± 0.07            0.30 ± 0.06   −0.1    0.005     \-
   39   cg23324787     RAG2      11   36576362    Gene body   FALSE           0.57 ± 0.08            0.67 ± 0.03   −0.1    0.005    0.007
   40   cg13041032     MMP13     11   102331672   Gene body   FALSE           0.64 ± 0.08            0.74 ± 0.03   −0.1    0.005    0.006
   41   cg10784090    CLDN18     3    139200348   Promoter    TRUE            0.59 ± 0.08            0.70 ± 0.04   −0.1    0.005     \-
   42   cg04317399     HOXA4     7    27136924    Gene body   TRUE            0.26 ± 0.07            0.38 ± 0.09   −0.12   0.006     \-
   43   cg27202708    C1orf65    1    221633391   Promoter    TRUE            0.22 ± 0.07            0.34 ± 0.08   −0.12   0.006     \-
   44   cg20300655   CATSPER3    5    134331513   Promoter    FALSE           0.64 ± 0.08            0.74 ± 0.02   −0.1    0.006    0.007
   45   cg10094277     KERA      12   89976262    Gene body   FALSE           0.51 ± 0.09            0.62 ± 0.03   −0.11   0.007    0.008
   46   cg04117029     UROS      10   127501757   Promoter    FALSE           0.60 ± 0.09            0.71 ± 0.03   −0.11   0.007    0.008
   47   cg12588299     GPR31     6    167491309   Promoter    FALSE           0.50 ± 0.08            0.61 ± 0.05   −0.11   0.007    0.008
   48   cg27269921      MN1      22   26527486    Gene body   TRUE            0.11 ± 0.03            0.23 ± 0.12   −0.12   0.007     \-
   49   cg10362591    SLC6A2     16   54248057    Promoter    TRUE            0.21 ± 0.06            0.33 ± 0.09   −0.12   0.007     \-
   50   cg02248486     HOXA5     7    27149812    Gene body   TRUE            0.47 ± 0.07            0.57 ± 0.07   −0.1    0.008     \-
   51   cg04616566     THSD4     15   69807942    Promoter    FALSE           0.60 ± 0.09            0.72 ± 0.03   −0.11   0.008    0.009
   52   cg19366178     GNB5      15   50270857    Promoter    FALSE           0.69 ± 0.09            0.79 ± 0.02   −0.1    0.008    0.008
   53   cg05259765     PSCD4     22   36008370    Promoter    TRUE            0.66 ± 0.08            0.77 ± 0.03   −0.1    0.009     \-

Gene ontology analysis of the differentially methylated genes in asthmatics atopic or non-atopic for *Df* and *Dp*
------------------------------------------------------------------------------------------------------------------

To examine the biological functions associated with the genes that had significantly hypomethylated and hypermethylated loci, we analyzed the gene ontologic categories of 52 hypomethylated and hypermethylated genes using the GOTM program (<http://bioinfo.vanderbilt.edu/gotm/>) \[[@B22]\]. The genes present on the Illumina methylation assay chip were used as a reference list. The genes with hypomethylated loci were assigned to the distinct gene ontologic categories of multicellular process, response to organic substance, hormone metabolic process, and growth factor receptor binding (Table [4](#T4){ref-type="table"} and Additional file [1](#S1){ref-type="supplementary-material"}: Table S2).

###### 

Gene ontology analysis of genes with different methylation states according to atopic status among BA

   **Methylation states**  **Category**         **Gene ontology category**               **Genes**                                                                                                                             **Observed gene number**   **Expected gene number**   **Ratio of enrichment**   **Significance of enrichment**
  ------------------------ -------------------- ---------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------ -------------------------- -------------------------- ------------------------- --------------------------------
      Hypomethylation      Biological process   Cellular hormone metabolic process       UGT1A1, CRYM, AKR1C4                                                                                                                             3                         0.21                      14.37                        0.001
                                                Positive regulation of DNA replication   PDGFC, UCN                                                                                                                                       2                         0.08                      25.06                        0.003
                                                Response to organic substance            IL1R1, UGT1A1, UROS, CDH1, CASP1, NR1H4, UCN                                                                                                     7                         1.97                      3.55                         0.003
                                                Porphyrin metabolic process              UGT1A1, UROS                                                                                                                                     2                         0.09                      23.27                        0.003
                                                Multicellular organismal process         UGT1A1, PDGFC, KERA, C4orf6, CATSPER3, CRYM, RAG2, NR1H4,KALRN, PKHD1, CLCN5, UCN, CDH1, HOXA4, HOXA5, PDE4D, MMP13, CASP1, SLC6A2               19                       10.87                      1.75                         0.004
                                                Monoamine transport                      CRYM, SLC6A2                                                                                                                                     2                         0.11                      18.62                        0.005
                                                Collagen metabolic process               MMP13, UCN                                                                                                                                       2                         0.12                      16.71                        0.006
                           Molecular function   Growth factor receptor binding           IL1R1, PDGFC, IL1F5                                                                                                                              3                         0.20                      14.83                        0.001
                           Cellular component   Extrinsic to plasma membrane             GNB5, CDH1                                                                                                                                       2                         0.14                      14.75                        0.008
      Hypermethylation     Biological process   Signal transduction                      MAP3K5, TACSTD2                                                                                                                                  2                         0.13                      15.73                        0.005
                                                Immune response                          RSAD2                                                                                                                                            1                         0.05                      14.96                        0.001
                                                metabolic process                        TIPARP                                                                                                                                           1                         0.05                      13.49                        0.004
                           Molecular function   Protein kinase activity                  MAP3K5                                                                                                                                           1                         0.04                      22.48                        0.002
                                                DNA binding                              TIPARP                                                                                                                                           1                         0.05                      18.76                        0.004
                                                Receptor activity                        TACSTD2                                                                                                                                          1                         0.03                      14.64                        0.009
                           Cellular component   Cell surface receptor                    TACSTD2                                                                                                                                          1                         0.04                      14.59                        0.009

P-values of enrichment significance below 0.01 were shown.

Discussion
==========

DNA methylation is essential for cell differentiation and development. Moreover, for many years, DNA methylation has observed to play a role in regulating gene expression. Methylation of gene promoter region is correlated with low or no transcription \[[@B23]\]. Recent research revealed novel insights on the location of DNA hypermethylation. Hypermethylation of intra- and intergenic CpG dinucleotides might contribute to regulating gene expression by functioning as alternative promoters \[[@B24]\]. For example, in-depth investigation of the human SHANK3 locus (\~60 kb) showed hypermethylation-regulated intragenic promoter activity, expressing alternative transcripts in a tissue- (brain) and cell-type (primary cortical astrocyte)--specific manner \[[@B24]\]. In addition, other gene-regulating regions such as enhancers, which are *cis*-regulatory DNA sequences that increase transcription independent of their orientation and distance relative to the TSS, can be regulated by hypermethylation \[[@B25],[@B26]\]. For example, hypermethylation-dependent enhancer-like activity, located at a CpG island in EGFR2 intron 1, is suggested to regulate transcription \[[@B27]\]. In the present study, the methylation levels in the three sample groups had an average β value that ranged from 0 to 0.2 for 50% of the loci on the entire methylome. Continuously expressed genes, including housekeeping genes, may be included in this group (Additional file [1](#S1){ref-type="supplementary-material"}: Table S3). The lowest peak, representing about 0.2% of the loci, was at the right end (average β, 0.9--1.0). These genes may be densely packed in nucleosomes. The methylation levels in the three sample groups showed a similar pattern. However, recent studies also identified positive associations between expression and methylation level \[[@B28]-[@B30]\]. Further gene expression analysis can be integrated with this DNA methylation data, and can reach about the exact role of DNA methylation in controlling gene expression.

Comparing the average β value for each locus in the bronchial mucosa tissues of the asthmatics atopic to house dust mites with those of the non-atopic asthmatics, 47 loci in 46 genes showed significant decreases in methylation, while 6 loci in 6 genes showed relative increases in methylation. These data suggest that the phenotypic differences in atopic sensitization to house dust mites originate from differences in gene regulation in the lower airways. Notably, the hypomethylated genes were linked to multicellular process, hormone metabolic process, response to organic substance, and growth factor receptor binding. Changes in the expression levels of these genes caused by hypomethylation might lead to sensitization to inhaled allergens, such as house dust mites or pollens.

In the present study, we did not examine the levels of mRNA expression in the bronchial mucosa of the subjects, since the mucosal biopsy samples were too small to extract DNA and RNA at the same time. However, one interesting finding is decrease of the methylation for mitogen-activated protein kinase 5 (*MAP3K5*) gene in non-atopic asthmatics compared to asthmatics atopic for *Dp*. The intronic SNP rs9494554, located within MAP3K5, was associated with atopy in the pooling and replication samples, and remained significant in the combined analysis after Bonferroni correction. Other SNP in MAP3K5 (rs9402839) was nominally significant for atopy in pooling sample and border significant in the replication step. MAP3K5 has been found to be associated with atopy \[[@B31]\]. *MAP3K5* encodes a member of the mitogen-activated protein kinase family that regulates the activation of the transcription factor activator protein-1(AP1) in leukotriene D4-stimulated airway smooth muscle cells and in nitric oxygen-stimulated bronchial epithelial cells \[[@B32],[@B33]\].

E-cadherin (CDH1) gene polymorphisms are associated with airway remodelling, inflammation and lung function decline in individuals with asthma. CDH1 SNPs are associated with epithelial E-cadherin expression and suggest that epithelial adhesion is an important contributor to airway remodeling and lung function in asthma \[[@B34]\].

In bronchial epithelial cells, Der p 2, which is a major non-proteolytic allergen of *Dp*, induced dose-dependent up-regulation of both mRNA expression and protein secretion of T cell-directed CC chemokine, granulocyte-macrophage colony-stimulating factor, IL6, IL8, monocyte chemotactic protein-1, and macrophage inflammatory protein-3a *via* NF-κB and MAPK activation \[[@B35],[@B36]\]. However, many of the genes identified in the present study have not been linked with atopy to *Dp*. Thus, further functional characterization of these genes is needed to clarify the relationship between the methylation of these genes and the development of atopy. These mechanisms include genomic imprinting, histone modification, altered DNA methylation of regulatory sequences, which may change asthma risk after conception via environmentally mediated epigenetic disruption of gene expression \[[@B37],[@B38]\]. Since the pattern of CpG island methylation is generally cell line-specific, the sampled airway mucosa should not differ in cellular composition between the groups. Previous studies comparing pathologic findings demonstrated that the histologic appearance of the bronchial mucosa from atopic asthmatics did not differ from that of non-atopic asthmatics \[[@B39]\]. Although we did not perform differential counts of the infiltrating cells and the cells comprising the bronchial mucosa, the extent of cellular infiltration, as assessed by hematoxylin and eosin staining, was similar in the two groups (data not shown). However, previous immunohistochemical studies of bronchial mucosa have shown different expression patterns of adhesion molecules, cytokines, chemokines, inflammatory mediators, and their receptors \[[@B40],[@B41]\]. Therefore, we consider that the difference in methylation patterns is associated with different stages of cellular differentiation or activation, rather than the cellular composition of the bronchial mucosa. The present study confirms the existence of atopy-associated methylation in bronchial mucosa tissues. The bronchial mucosa samples from asthmatics with atopy show characteristic methylation patterns for 52 genes. In addition Limitations of this study are the relatively small sample size, limited statistical power, and the lack of gene expression data. Further investigation is required for a direct correlation analysis between expression and methylation. In addition, the confounding effects of contaminated tissues are also possibly influencing methylation levels.

Conclusions
===========

Our DNA methylation profiles served as a robust discriminator between asthmatics who are atopic or non-atopic for the *Dp* antigen. Functional studies will be valuable in identifying key genes or pathways that could serve as biomarkers or therapeutic targets.
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